Connect with us

Media OutReach

Johnson & Johnson launches The 3rd Opinion in Asia Pacific: a new term to elevate the patient voice in the lung cancer treatment journey

Published

on

  • Newly published research shows up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making1.
  • A new term, coined The 3rd Opinion, is designed to spark a social movement that empowers patients to recognize their vital role in shared decision-making, in a region that is disproportionately impacted by lung cancer2.

SINGAPORE –

According to newly published data on NSCLC patient preferences in Future Oncology, up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making[1]. Cultural norms around stigma, not questioning authority, and limited understanding of the disease can often be major barriers causing patients not to voice concerns or ask questions, even when healthcare professionals actively encourage their input.

“Being diagnosed with lung cancer is overwhelming. It’s natural for patients to seek clarity, often by pursuing a second opinion, to better understand their condition and treatment options. However, patients often hesitate to express their concerns and treatment goals, causing them to be overlooked in the decision-making process. By creating space for the patient’s own opinion, The 3rd Opinion, creates a new way of thinking about lung cancer treatment and empowers patients to find their voice,” said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific.

J&J IM Key Visual Reunion The 3rd Opinion

Lung cancer has the highest incidence and mortality rate of all cancers worldwide, with more than 2.5 million people diagnosed every year, and Asia makes up 63% of all patients[2]. Up to 85% of lung cancers are non-small cell lung cancer (NSCLC) and Asians are more prone to certain genetic mutations than the rest of the world. One of the most prevalent is a mutation known as EGFR where 30-40% of all NSCLC diagnoses are in Asia, compared to 10-15% in the United States and Europe[3][4][5]. Often being diagnosed at a late stage, less than 20% of people with these genetic mutations survive beyond five years[6], and up to 40% never get the chance to receive a subsequent therapy after first-line treatment.[7][8][9]

“With the disproportionately high prevalence of certain NSCLC mutations in Asia Pacific, we need to think differently about how we treat patients and what more we can achieve with the first treatment. Treatment options have become increasingly complex and clinical decision making should comprehensively consider disease characteristics, patient treatment goals and values, and aim for an individualized balance between survival, longer lasting disease control and side effects. When shared decision making includes all available options, the final decision can be made collaboratively,” said Prof James Chih-Hsin Yang, Director of National Taiwan University Cancer Center and key advocate for The 3rd Opinion initiative.

J&J IM Key Visual Wedding The 3rd Opinion

Mark Brooke, Chief Executive Officer of Lung Foundation Australia, co-author of the Future Oncology publication and an advocate of The 3rd Opinion agreed, “The physician and patient dynamic is one of trust, but we cannot rely on that alone. The consequence is a potential disconnect between the patient and their healthcare professional around treatment preferences and personal goals. For patients, they often want more time above all else – to witness life’s milestones, more moments with loved ones, and more opportunities to simply live. Patients need to be equipped with adequate disease and treatment information, so they can communicate what matters most to them”.

J&J IM Key Visual Grandchild The 3rd Opinion

The 3rd Opinion will be launched across multiple markets with educational resources, including a Lung Cancer Book of Answers in China, a patient empowerment video and various shared decision making tools across Asia Pacific to spark a social movement that encourages patients to confidently articulate their personal goals for treatment. The creation of a neologism, like The 3rd Opinion, ensures shared decision making becomes accepted into clinical practice and in turn fosters an environment where the doctor’s expertise and the patient goals come together to design the best treatment plan.


[1] Chee Khoon Lee et al. Navigating advanced lung cancer care, patient–physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians. DOI: 10.1080/14796694.2025.2499511

[2] Natia Jokhadze MD, Arunangshu Das MBBS, Don S. Dizon MD. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Volume 74Issue 3CA: A Cancer Journal for Clinicians pages: 224-226 First Published online: April 4, 2024

[3] Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology. 2011; 29(15): 2121-2127.

[4] Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. Journal of Clinical Oncology. 2013; 66(2): 79-89.

[5] Korpanty G, et al. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology. 2014; 4: 204.

[6] Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154-161.​

[7] Nieva J, Karia PS, Okhuoya P, et al. A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer [ESMO abstract 1344P]. Ann Oncol. 2023;34(suppl 2):S774 ​

[8] Lee JY, Mai V, Garcia M, et al. Treatment patterns and outcomes of first-line osimertinib-treated advanced EGFR mutated NSCLC patients: a real-world study [IASLC abstract EP08.02-082]. Presented at: IASLC 2022 World Lung Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria.​

[9] Girard N, Leighl NB, Ohe Y, et al. Mortality among EGFR-mutated advanced NSCLC patients after starting frontline osimertinib treatment: a real-world, US attrition analysis. Presented at: the European Lung Cancer Congress; March 29-April 1, 2023; Copenhagen, Denmark. Poster 19P.​

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About The 3rd Opinion

“The 3rd Opinion”, the patients own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[10], [11] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[12] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[13] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[14], [15],[16],[17],[18],[19] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[20] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent. [21], [22] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[23] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[24]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[25].


[10]The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[11] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[12] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[13] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[14] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[15] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[16] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[17] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[18] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[19] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[20] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[21] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[22] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[23] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[24] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[25] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at or at . Follow us at .

Advertisement

Media OutReach

Tanoto Foundation Convened Global and National Leaders to Strengthen the Early Childhood Education and Development (ECED) Ecosystem at the 2025 International Symposium on ECED

Published

on

SINGAPORE – Media OutReach Newswire – 29 December 2025 – Tanoto Foundation convened government leaders, international organisations, researchers, and civil society at the 2025 International Symposium on Early Childhood Education and Development (ECED), in Jakarta under the theme “ECED Ecosystem Synergy in Promoting the Best Start in Life.

The symposium comes at a critical moment, as shared challenges across health, nutrition, education, and caregiving continue to shape early childhood development outcomes in Indonesia and globally, where many young children continue to face barriers to healthy development, from gaps in nutrition and care to limited access to quality early learning.

These challenges highlight the need for closer coordination across health, education, parenting, and social protection to ensure children receive holistic and equitable support from the earliest years.

Without strong cross-sector collaboration, Indonesia risks losing momentum in building its human capital and realising its demographic dividend towards Indonesia Emas 2045.

In partnership with key government ministries and cross-sector organisations, Tanoto Foundation convened the symposium as a platform to align policy, practice, and evidence across sectors, bringing together representatives from central and local government, international organisations, academia, civil society, and philanthropy.

The symposium featured two main discussion tracks focused on health and education, and parenting in early childhood.

The morning segment, “Synergising Health and Education for ECED”, focused on integrating health, nutrition, and early learning services, highlighting innovations in growth and development monitoring, nutrition interventions, and early stimulation within primary service systems.

The afternoon session, “Parenting and Early Learning”, placed families and caregivers at the centre of the ECED ecosystem, exploring responsive caregiving, interaction-based learning, and policy support to strengthen parents’ capacity to nurture children’s development.

Indonesian Minister of Health Budi Gunadi Sadikin officially opened the symposium, emphasising the decisive importance of early childhood for national development.

“The age of 0 to 5 years is a highly decisive phase in determining whether a person will grow into a healthy, intelligent adult who can contribute to the nation, including to increase per capita income,” the Minister said.

“If we do not act quickly, we risk missing Indonesia’s demographic dividend. This is our responsibility to our children.”

The Government of Indonesia has reaffirmed early childhood development as a national priority through the Long-Term National Development Plan 2025 to 2045 and the Medium-Term National Development Plan 2025 to 2029, with Holistic and Integrated Early Childhood Development (PAUD-HI) designated as a key performance indicator.

Opening the afternoon session, Indonesian Minister of Women Empowerment and Child Protection, Arifatul Choiri Fauzi, highlighted the symposium’s contribution to policy strengthening.

“This forum brings together strategic cross sector perspectives. We encourage the resulting recommendations to be used to strengthen policies, regulations, and service innovations for early childhood development,” she said.

Indonesian Deputy Minister of Higher Education, Science, and Technology, Prof. Stella Christie, underscored the importance of science-based parenting and high-quality interaction.

“Caregiving with optimal interaction between children and caregivers has the greatest potential to maximise child development,” she said. “No technology, including artificial intelligence, can replace the power of human interaction.”

She added that children learn through curiosity, imitation, and everyday experiences, making responsive and evidence-based parenting critical for brain development and lifelong learning.

CEO of Tanoto Foundation Benny Lee reaffirmed the Foundation’s long-term commitment to early childhood development as a cornerstone of human potential.

“The early years are when the foundations of brain development, health, and character are formed,” Benny said.

“This is not the work of one institution. It requires a truly supportive ecosystem built through collaboration among government, civil society, academia, and philanthropy.”

He emphasised that Tanoto Foundation, founded by Sukanto Tanoto, Founder and Chairman of Royal Golden Eagle (RGE), views early childhood development as a primary investment, where collective action can deliver lasting and sustainable impact. “This symposium is about ensuring that every child receives the strongest possible start in life, every parent receives the support they need, and every sector moves forward together,” he said.

The symposium brought together up to 200 participants, with speakers from government, development organisations, academia, research institutions, and philanthropy.
Hashtag: #RGE #TanotoFoundation #Philanthropy #Indonesia #ECED #EarlyChildhood #Healthcare

The issuer is solely responsible for the content of this announcement.

About Tanoto Foundation

At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realise his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes.

Continue Reading

Media OutReach

Can Gio Awakens as Ho Chi Minh City’s Next Growth Frontier

Published

on

After decades of quiet, Can Gio is awakening on Vietnam’s southern coast, as fresh investment and grand designs breathe new life into the once-remote district of Saigon.

HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 27 December 2024 – Six months after the groundbreaking of a 2,870-hectare coastal urban project backed by Vingroup, Vietnam’s largest private conglomerate, Can Gio, once seen as a forgotten corner of Ho Chi Minh City, is now emerging as a new growth engine for Vietnam’s southern metropolis.

Vinhomes Green Paradise: A Hidden Gem Poised to Shine in Vietnam’s Real Estate Market.

Breaking Isolation

For years, Can Gio was often left out of the city’s rapid development. Surrounded by dense forests and accessible mainly by ferry, it remained a world apart. Now, that is beginning to change.

Six months ago, the large-scale land reclamation project officially started construction. Locals call it a “game changer” that awakened a land long left behind. Along the coast that once lay quiet, a vast construction site has emerged, with heavy machinery working day and night. “I was very surprised by the speed,” said Prof. Pham Van Song, president of the Mien Dong University of Technology, noting that hundreds of hectares have already been filled and stabilized within months.

The project, developed by Vingroup through its real estate arm Vinhomes, represents one of the group’s most ambitious coastal developments, part of a long-term vision to extend Ho Chi Minh City’s urban footprint toward the sea. With billions of U.S. dollars in investment, it combines housing, tourism, and modern infrastructure within a single master plan that anchors Can Gio’s transformation.

Complementing this project, a series of major infrastructure works are also reshaping the district. By the end of 2025, the Phu My Hung–Can Gio high-speed railway, designed to reach 350 kilometers per hour, is expected to begin construction, linking the area to the city’s southern urban core. In 2026, the long-awaited Can Gio Bridge will break ground, cutting the journey to the city center to around 45 to 60 minutes.

At the same time, the Rung Sac interchange, with an investment of 3,000 billion VND (about 120 million U.S. dollars), will connect Can Gio directly with the Ben Luc–Long Thanh Expressway. Expected to be completed in 2028, it will link Can Gio with both the Southwest and Southeast regions, including Long Thanh International Airport.

In addition, a sea-crossing expressway between Can Gio and Vung Tau, 50 meters wide and proposed by Vingroup, would stretch across the sea for more than 10 kilometers. The plan envisions a wide eight-lane road that could reduce travel between Can Gio and Vung Tau to under 15 minutes, creating a strategic connection between the two coastal economies.

These efforts fit within a broader regional plan that combines road, rail, water, and sea transport. Another key project is the Can Gio International Transshipment Port, covering 571 hectares with an investment of 50,000 billion VND. The port is designed to become a new symbol of Vietnam’s maritime economy, with its first phase scheduled to begin operations in 2027 and full completion before 2045.

“A Single Project Ignites the South”

According to Prof. Pham Van Song, the rise of Can Gio is a natural development, especially with the involvement of Vingroup through its Vinhomes Green Paradise project. He believes that Can Gio is moving from an ecological area on the fringe of development to a new center of growth. “All modes of transportation will be available in Can Gio,” he said. “The district’s GRDP will grow rapidly in line with ongoing construction and investment. Both the number of residents and visitors will surge. Local people will be the first to directly benefit from these projects, and their lives will become increasingly prosperous.”

The changes are already drawing attention from investors. Dinh Minh Tuan, southern regional director of Batdongsan.com.vn, said the number of searches related to Can Gio has tripled since the beginning of the year. After the Vinhomes Green Paradise project broke ground, property interest in the district doubled again. “Just one single project has heated up the entire southern market,” he said.

Experts say this follows a familiar pattern. In the 1990s, Nguyen Van Linh Boulevard helped turn southern Ho Chi Minh City into a thriving area and drew nearly two million residents. In the 2010s, the completion of the Thu Thiem Tunnel and Bridge attracted more than one million people to the city’s east. “Investors who followed the infrastructure development wave then saw huge gains,” Tuan noted. “Can Gio now stands at a similar starting point, but with a stronger push.”

With a population of about 80,000, Can Gio has long faced a single challenge: lack of connectivity. But, “with the series of large-scale investments now under way, Can Gio is expected to grow faster than many of the city’s earlier new urban areas,” said Tuan.
Hashtag: #Vinhomes

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Z.ai Open-Sources GLM-4.7, a New Generation Large Language Model Built for Real Development Workflows

Published

on

SINGAPORE – Media OutReach Newswire – 26 December 2025 – Z.ai has released GLM-4.7, the latest version of its open-source large language model, ahead of Christmas, as the company steps up efforts to position its models for real-world software development and production use.

The new model is designed around practical engineering workflows, with a focus on long-running task execution, stable tool calling, and multi-step reasoning, capabilities that have become increasingly important as developers deploy large language models in complex, agent-based systems.

Compared with its predecessor, GLM-4.6, GLM-4.7 shows notable gains in code generation, complex reasoning, and agent execution. According to Z.ai, the model delivers more consistent and controllable performance over extended tasks, while producing cleaner and more concise language output, addressing a common weakness in many open-source models.

To evaluate performance in realistic settings, Z.ai tested GLM-4.7 on 100 practical programming tasks in production-like environments such as Claude Code, spanning front-end, back-end, and command-execution scenarios. The company said GLM-4.7 achieved higher task completion rates and greater stability than GLM-4.6, and has since been adopted as the default model for its GLM Coding Plan.

Benchmark results also place GLM-4.7 among the strongest open-source models currently available. It scored 67.5 on BrowseComp and 87.4 on τ²-Bench, the latter marking a new high for open-source systems. In coding-focused evaluations, including SWE-bench Verified and LiveCodeBench v6, its overall performance approaches that of Claude Sonnet 4.5. In Code Arena’s large-scale blind evaluation, which aggregates votes from more than one million comparisons, GLM-4.7 ranked first among open-source models.

The model is available through the BigModel.cn API and has been integrated into Z.ai’s full-stack development platform, according to the company. As open-source models take on a more prominent role in the global technology ecosystem, Z.ai’s progress offers a clear indication of how such systems may continue to evolve, and what they might enable next.

Default Model for Coding Plan: https://z.ai/subscribe
Try it now: https://chat.z.ai/
Weights: https://huggingface.co/zai-org/GLM-4.7
Technical blog: https://z.ai/blog/glm-4.7

Hashtag: #ZAI

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending